ADVERSE TRANSFUSION EVENTS
-
Upload
lane-walters -
Category
Documents
-
view
62 -
download
1
description
Transcript of ADVERSE TRANSFUSION EVENTS
![Page 1: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/1.jpg)
ADVERSE TRANSFUSION EVENTS
HEMATOLOGY ROUNDSAugust 23, 2012
D.K. Towns, MD, FRCPC (Anesthesia)Medical DirectorCanadian Blood ServicesCalgary, AB
![Page 2: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/2.jpg)
2
OVERVIEW OF THE CANADIAN BLOOD SYSTEM
![Page 3: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/3.jpg)
3
The blood system in Canada is complexRegulator
Health Canada
Blood Suppliers
Canadian Blood Services (CBS)
Hema-Quebec (H-Q)
![Page 4: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/4.jpg)
4
Government funding for CBS is approved by a provincialcommittee.
The CBS Head Office is located in Ottawa and has overallresponsibility for:
a) developing policies and standard operating procedures
b) monitoring collection facilities and regional testing laboratories
c) developing contracts with plasma fractionators to fractionate CBS plasma and obtain fractionation products
![Page 5: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/5.jpg)
5
Regional CBS staff include administrative, medical, nursing, technical, and recruitment personnel who are responsible for:
a) recruiting, assessing, and monitoring donors during blood or apheresis collections
b) processing, storing, distributing, and transporting blood components and products to area hospitals
c) performing laboratory testing or arrange for centralized laboratory testing
d) conducting quality control activities
e) maintaining lookback/traceback programs
![Page 6: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/6.jpg)
6
Partners in the Health Care system include:
1) Hospital Transfusion Laboratories
2) Clinical staff in hospitals
3) The blood recipients’ physician who orders blood transfusion
![Page 7: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/7.jpg)
7
* Source: Courtesy of Canadian Blood Services, Clinical Guide to Transfusion, pg 13.
![Page 8: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/8.jpg)
8
A few "facts”• Canadian Blood Services has 43 permanent locations
and services 732 health facilities
• We have 1.74 million donors
• Only 3.7% of eligible Canadians are blood donors (excluding Quebec)
• 21% of donors are aged 17-24
• 79% of donors are aged 25+
• 49% male/51%female
![Page 9: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/9.jpg)
9
A few more "facts”
• Last year we collected:– 910,220 units of whole blood– 54, 432 units of apheresis plasma– 54,432 units of apheresis platelets– 963 units of autologous blood– 189 units of blood for directed donation
• Each unit of whole blood can be made into up to 3 components:– red blood cells– plasma– platelets or cryoprecipitate
![Page 10: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/10.jpg)
10
![Page 11: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/11.jpg)
11
Adverse Event
"An undesirable and unintended response to the administration of whole blood or a blood component that is considered to be definitely, probably, or possibly related to the administration of whole blood or blood component."
(also referred to as Adverse Transfusion Reaction, or Adverse Transfusion Event)
![Page 12: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/12.jpg)
12
Serious Adverse Event• requires in-patient hospitalization or prolongation of
hospitalization directly attributable to the event
• results in persistent or significant disability or incapacity
• necessitates medical or surgical intervention to preclude permanent damage to, or impairment of body function
• is life-threatening
• results in death
![Page 13: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/13.jpg)
13
Unexpected Adverse Event
An adverse event that is not identified in nature, severity, or frequency among the currently known adverse effects associated with the administration of blood, blood components, or blood products (plasma derivatives).
![Page 14: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/14.jpg)
14
Canadian Blood Services requires that hospitals report adverse transfusion reactions to us
We, in turn, report these reactions to Health Canada
![Page 15: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/15.jpg)
15
Why?• May result in product recall.
• May result in donor notification and/or investigation and/or deferral.
• May result in recipient notification.
• Also required for purposes of tracking and trending (?something new; ?an unexpected change in frequency)
![Page 16: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/16.jpg)
16
Timelines
Serious Adverse Event resulting in Fatality:• report immediately to MD and QAM• report immediately to Director, Regulatory Affairs
• report as soon as possible after discovery of event to MD and QAM
• report as soon as possible but no later than eight working days from the discovery of the event to Director, Regulatory Affairs
Other Serious Adverse Event (non-fatal) or Unexpected Adverse Event
![Page 17: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/17.jpg)
17
Canadian Blood Services’ Medical Director is responsible for assessing the information:• description of events preceding and following the reaction
including date, time, diagnosis, drug history, clinical symptoms, and sequelae
• identify transfused components requiring investigation within appropriate timeframes including donation numbers and dates of collection
• identify and consult with the reporting facility (if required) the feasibility of initiating additional patient/product testing
• determine ATE classification
• determine requirement for recall of companion components and/or recall of previous donations, including final disposition of recalled components
![Page 18: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/18.jpg)
18
Canadian Blood Services’ Medical Director is responsible for assessing the information (cont’d):
• determine requirement for donor deferral/notification
• determine requirement for surveillance event initiation and addition of tests pending on next donation
• review donor record(s) in PROGESA to determine if any associated donor(s) were ever associated with a previous AR type of surveillance event
• determine additional comments/actions required
• defer donors if required
![Page 19: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/19.jpg)
19
![Page 20: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/20.jpg)
Clinical diagnosis• When any unexpected or untoward sign or
symptom occurs during or shortly after the transfusion of a blood component, a transfusion reaction must be considered as the precipitating event until proven otherwise.
• Only a high index of suspicion will allow a transfusion reaction to be diagnosed.
20
![Page 21: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/21.jpg)
Immediate Adverse Events Associated with Transfusion
• Acute hemolytic transfusion reaction• Febrile non-hemolytic transfusion
reaction• Allergic Reactions
– urticarial– anaphylactic
• Transfusion-associated circulatory overload (TACO)
• Transfusion-associated dyspnea (TAD)
• Transfusion-related acute lung injury (TRALI)
21
• Septic transfusion reaction (bacterial contamination)
• Hypotensive reactions– ACE inhibitors
• Non-immune red cell hemolysis• Metabolic disturbances
– hypothermia– hyperkalemia– acidosis
![Page 22: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/22.jpg)
Risk of Complication
22
REACTION RATE
Acute hemolytic transfusion reaction 1:25,000
Febrile non-hemolytic transfusion reaction 1:10 (platelets)
Allergic reaction: Anaphylactic 1:40,000
Allergic reaction: Minor 1:100
TRALI 1:5,000
TACO 1:700
![Page 23: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/23.jpg)
Delayed Adverse Events Associated with Transfusion
• Delayed hemolytic transfusion reaction• Alloimmunization
– Red cell antigens– HLA– Leucocytes– Platelets
• Graft versus host disease (TA-GVHD)• Post-transfusion purpura (PTP)• Hemosiderosis• Viral and parasitic infections• Transfusion-related immunomodulation (TRIM)
23
![Page 24: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/24.jpg)
Signs and Symptoms of Transfusion Reactions
• fever/chills/rigors• pain• dyspnea/
respiratory distress• bleeding• hypotension• hypertension• headache
24
• nausea and vomiting
• rash/hives• angioedema• flank pain• anaphylaxis• cyanosis• bronchospasm
• tachycardia• abdominal
cramps• diarrhea• cough• red eye• anxiety• jaundice• hematuria
![Page 25: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/25.jpg)
Often difficult because:
• there is more than one predominant presenting symptom
• more than one reaction going on• atypical presentation
• underlying comorbidities unrelated to transfusion
25
![Page 26: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/26.jpg)
Shortness of Breath
26
![Page 27: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/27.jpg)
Differential Diagnosis of transfusion reaction with
shortness of breath:• TRALI• TACO• TAD• Anaphylaxis• AHTR• Bacterial contamination• Other etiology (unrelated to transfusion)
27
![Page 28: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/28.jpg)
TRALI
• Acute onset (within 6 hours of transfusion)• Hypoxemia• Bilateral infiltrates on CXRay• No evidence of circulatory overload• No pre-existing acute lung injury or other risk factors for ALI
May also have– hypotension– fever– transient leucopenia
Minimal findings on chest auscultation
28
![Page 29: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/29.jpg)
TRALI continued
TTISS (2004-2005) - 2nd highest cause of transfusion-related morbidity and mortality
Treatment: ventilation support
80% of patients show clinical improvement within 48-96 hours
5 - 10% fatality
29
![Page 30: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/30.jpg)
TACO• Acute pulmonary edema secondary to congestive heart failure precipitated by
transfusion of a blood volume greater than what the recipients circulatory system can tolerate
(** do not need a "sick heart" to suffer iatrogenic CHF**)
• Hypertension• Tachycardia• Positive fluid balance
Likely the most under-recognized and potentially serious transfusion complication
Risk factors:– too much blood transfused too rapidly– age <3 or > 60 years– diminished cardiac reserve– chronic (volume-compensated) anemia
30
![Page 31: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/31.jpg)
TACO continuedPrevention• transfuse only when indicated• recognize patients at risk• if at-risk, transfuse slowly• consider diuretics• watch fluid balance - invasive monitoring if at-risk patient or high-risk
transfusion (example: massive transfusion)
Treatment• stop transfusion• position patient in upright position• supplementary oxygen• diuretics• cardiac and respiratory support as required
31
![Page 32: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/32.jpg)
Transfusion Associated Dyspnea (TAD)
European Haemovigilence Network introduced the term to allow for classification of respiratory distress temporally associated with transfusion which could not be assigned
to known pulmonary reactions
32
![Page 33: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/33.jpg)
Immediate management of a transfusion reaction associated with shortness of breath:
• Stop the transfusion immediately• Notify hospital blood bank of transfusion
reaction• Maintain IV access • Monitor patient’s vital signs• Recheck patient ID and blood product
label• Chest X-ray
33
![Page 34: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/34.jpg)
Fever
34
![Page 35: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/35.jpg)
Differential diagnosis of fever associated with a transfusion reaction:
• Acute Hemolytic transfusion reaction• Febrile non-hemolytic transfusion reaction• Bacterial sepsis or contamination• TRALI• Etiology unrelated to transfusion
35
![Page 36: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/36.jpg)
AHTRAccelerated clearance of red cells in a transfusion recipient due to immunologic incompatibility between the blood donor and the recipient
Antigen-positive red cells are transfused to a recipient who has incompatible allo-antibodies
Results in intravascular hemolysis
Generally within the top 3 causes of transfusion-related mortality
Often due to the administration of ABO incompatible blood– cross-match error– wrong identification of blood specimen– blood administered to wrong patient
May rarely be due to recipient allo-antibodies to other red cell antigens
36
![Page 37: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/37.jpg)
AHTR continuedAcute onset : often within first 15 minute of starting transfusion (as little as 20-30 ml)
Initial presentation: fever, chills, anxiety, nausea, vomiting, pain (flank, abdomen), dyspnea, hypotension, brown urine, bleeding
Complications: renal failure, DIC, death
Treatment:– stop transfusion immediately– begin infusion with normal saline– alert blood bank, c heck for clerical error, sent entire transfusion set-up
for testing
Supportive care: monitor vital signs, maintain BP and urine output, monitor for hyperkalemia, treat any resulting coagulopathy
37
![Page 38: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/38.jpg)
Febrile Non-hemolytic Transfusion Reaction
Common adverse event– 1 in 10 transfusions of pooled random donor platelets– 1 in 3000 units of RBCs
Frequency varies with:– type of blood product– age of blood product– WBC content of blood product– recipient characteristics– ? pre-medication– variability in recording of symptoms
38
![Page 39: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/39.jpg)
FNHTR - continuedEtiology:• reactions mediated by antibodies (recipient alloantibody reactive to antigens
on WBCs in component)• reactions mediated by biologic response molecules
Clinical Presentation:• Fever (>1°C rise) during or soon after transfusion (5 - 10% present 1-2
hours after transfusion)• Chills and rigors• Nausea and vomiting
Treatment:• Stop the transfusion and assess patient• Rule out other more serious causes (AHTR, bacterial contamination)• Tylenol +/- Demerol• continue transfusion cautiously
39
![Page 40: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/40.jpg)
Bacterial ContaminationComponent Bacterial
ContaminationSymptomatic
Septic Reactions
Fatal Bacterial Sepsis
Platelet Pool 1 in 1,000 1 in 10,000 1 in 40,000
RBC (1 unit) 1 in 50,000 1 in 100,000 1 in 500,000
40
This is the most frequent infectious risk associated with transfusion
Accounts for about 11% of deaths due to blood components
Occurs most frequently with platelets
(Stored at 20 - 24° C -- excellent growth medium for bacteria)
![Page 41: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/41.jpg)
EtiologyBlood components may be contaminated by:
• unrecognized bacteremia in the donor (ex Yersinia enterocolitica)
• skin organisms from the donor (ex staphylococcus epidermidis)– difficult to totally decontaminate surface of skin– small core of skin may enter phlebotomy needle at
time of donation
• contamination from the environment or handling of the product (ex Serratia marcescens)– leaky seals, damaged tubing, etc.
41
![Page 42: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/42.jpg)
Commonly Implicated Bacteria
Gram-positive:
• Staphylococcus aureus
• Staphylococcus epidermidis
• Bacillus cereus
42
Gram-negative:
• Klebsiella pneumoniae
• Serratia marcescens
• Pseudomonas species
• Yersinia enterocolitica
![Page 43: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/43.jpg)
Clinical PresentationDepends on bacterial load and species of bacteria
• rigors, fever, chills• hypotension• tachycardia• nausea and vomiting• dyspnea• DIC
Usually occurs during transfusion of the implicated product
43
![Page 44: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/44.jpg)
Management and Investigation• Stop the transfusion immediately
• Notify the hospital blood bank
• Return residual product and tubing to blood bank
• Collect peripheral blood samples for culture
• Aggressive supportive therapy
• Broad spectrum therapy
44
![Page 45: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/45.jpg)
Differential Diagnosis of a Transfusion Reaction with Fever
Febrile non-hemolytic transfusion reaction– usually temp < 39° C– during transfusion; usually towards the end
Bacterial contamination– hypotension, shock, DIC– usually within first 15 minutes of a transfusion
AHTR• flank pain, DIC, hypotension• usually within first 15 minutes of transfusion
TRALI– SOB, hypoxemia, hypotension– within 6 hours of transfusion (usually during)
45
![Page 46: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/46.jpg)
Allergic ReactionUsually due to soluble allergenic substances in the plasma of donated blood
– react with pre-existing IgE antibodies in the recipient– causes release of histamine from mast cells and basophils
Possible mechanisms– pre-existing anti-IgA in IgA-deficient patient– pre-existing antibodies to other serum protein that patient is
lacking (IgG, Albumin, haptoglobin, alpha1-antitrypsin, transferrin, C3, C4, etc.)
– passive transfer of IgE antibodies– transfusion of allergen to which patient is sensitized to (drugs,
chemicals)
46
![Page 47: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/47.jpg)
Incidence:• mild 1:33 – 1:100 (1-3%)• severe 1:20,000 - 1:47000
Timing• during transfusion, or up to 3 hours from
the start of presentation
47
![Page 48: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/48.jpg)
Signs and Symptoms• hives• pruritis• angioedema• cough and wheezing• nausea and vomiting• abdominal pain• diarrhea• hypotension• cyanosis• tachycardia
48
![Page 49: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/49.jpg)
Signs & Symptoms of Serious Reactions
• hypotension/shock• shortness of breath, hypoxemia• cough• tachycardia• nausea and vomiting• generalized flushing or aniety• widespread rash (>2/3 of body)
49
![Page 50: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/50.jpg)
ManagementNon-serious:• antihistamine
- diphenhydramine 25-50 mg PO/IV• continue transfusion with caution• stop transfusion if any "serious" symptoms
Serious:• stop transfusion and do not restart• notify hospital transfusion service• epinephrine• antihistamine• corticosteroids• supportive therapy as required
50
![Page 51: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/51.jpg)
Summary
Initial management of transfusion reaction– stop transfusion immediately– notify blood bank– maintain IV access– monitor patient's vital signs– recheck identification of patient
Assess for symptoms of "serious" reaction
51
![Page 52: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/52.jpg)
What actions does Canadian Blood Services take when
these are reported?Immediate:• assess need for companion component recall• assess need for in-date component recall from same donor• assess need for hospital notification about potential component
problem
Next step:• assess need for additional product testing• assess need for lot number investigation
Possibly:• assess need for donor notification, testing, deferral
52
![Page 53: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/53.jpg)
Health Canada Reporting
• tracking trending...
53
![Page 54: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/54.jpg)
54
TACO
This is an iatrogenic clinical issue, and not a product problem.
However, we continue to receive these reports. (frequently because there is an uncertainty as to whether or not it is TRALI)
![Page 55: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/55.jpg)
55
ABO incompatibility
Health Canada does not require this information from CBS. (Provided labelling is correct!)
![Page 56: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/56.jpg)
56
TTISS(Transfusion Transmission
Injuries Surveillance System)
• Public Health Agency of Canada
• Electronic reporting from hospitals directly to PHAC
• Most, but not all hospitals, are providing this information
• DOES include reports of "wrong unit to wrong patient"
• Reconciliation of reports with CBS and Héma-Québec
• Last annual Program Report printed 2004/2005 (is available on-line)
![Page 57: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/57.jpg)
57
Plasma Protein Products
• Direct reporting from hospitals to Health Canada (CBS may, or may not be in the loop)
• This includes both patient reactions, as well as product complaints
• The manufacturer investigates, and sends CBS the report (… I send a copy to the relevant hospital).
• Also extremely useful for trending. (example - hemolysis associated with IVIg)
![Page 58: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/58.jpg)
What about current infectious disease risk?
O’Brien SF, Yi Q-L, Fan W, Scalia V, Fearon MA, Allain J-P. Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services. Vox Sang. 2012;103:83-6.
Incident rates estimated for allogeneic whole blood donations 2006-2009 . Based on transmissible disease conversions of repeat donations with a 3-year period.
Residual risk of:
HIV 1 per 8 million donations
HCV 1 per 6.7 million donations
HBV 1 per 1.7 million donations
58
![Page 59: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/59.jpg)
59
Adverse Reactions
ARs by Category
0
5
10
15
20
Sep-
09
Oct-09
Nov-09
Dec-09
Jan-1
0
Feb-
10
Mar-1
0
Apr-1
0
May-1
0
Jun-1
0Ju
l-10
Aug-
10
Sep-
10
Potential product problem Known complication
Analysis:• There were 130 ARs reported from September 2009 to September 2010; none were related to an error by
CBS.• There were 10 ARs reported in September 2010, within the statistical range of 4 to 16.
Results:The column chart to the left, ARs by Category, illustrates the ARs as categories based on the type of reaction. The 5 most prevalent/noteworthy are bar graphed.
1. Known Complication of transfusion (e.g. allergic, anaphylactic, febrile, PTP, acute/delayed hemolytic). 7 of these were reported to HC in September 2010.
• 2 Allergic• 1 TACO• 1 PTP• 1 Febrile• 2 Miscellaneous
2. Potential Product Problem of transfusion (e.g. TRALI, bacterial sepsis, transfusion transmitted WNV). There were 2 suspected TRALI reactions and 1 suspected Bacterial reaction reported to HC in September 2010.
TRALI suspected• 1 RBC (male)• 1 FFPA (male)
Bacterial Suspected• Patient and 1 unit positive for gram negative bacilli
ARs, Cumulative 13 months: n = 130
2%
13%
5%
5%
2%
6%
6%15% 17%
29%
Suspected TRALI (39)
Febrile (23)
TACO (19)
Suspected Bacterial (8)
Allergic (8)
Anaphylactic (6)
Delayed Hemolytic (6)
Acute Hemolytic (2)
PTP (2)
Miscellaneous (17)
Most prevelant ARs reported to Health Canada
0
1
2
3
4
5
6
7
Suspected TRALI Allergic Febrile TACO Suspected Bacterial
Sep-09
Oct-09
Nov-09
Dec-09
Jan-10
Feb-10
Mar-10
Apr-10
May-10
Jun-10
Jul-10
Aug-10
Sep-10
![Page 60: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/60.jpg)
60
![Page 61: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/61.jpg)
61
![Page 62: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/62.jpg)
62
![Page 63: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/63.jpg)
63
![Page 64: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/64.jpg)
64
![Page 65: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/65.jpg)
65
![Page 66: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/66.jpg)
66
![Page 67: ADVERSE TRANSFUSION EVENTS](https://reader037.fdocuments.net/reader037/viewer/2022103006/56812c58550346895d90e1a8/html5/thumbnails/67.jpg)
67
? QUESTIONS ?
? SUGGESTIONS ?